SG Americas Securities LLC grew its stake in shares of La Jolla Pharmaceutical (NASDAQ:LJPC) by 394.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 375,986 shares of the biopharmaceutical company’s stock after buying an additional 299,995 shares during the quarter. SG Americas Securities LLC owned about 1.39% of La Jolla Pharmaceutical worth $3,309,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in the business. FMR LLC raised its position in shares of La Jolla Pharmaceutical by 3.3% during the 1st quarter. FMR LLC now owns 4,061,425 shares of the biopharmaceutical company’s stock worth $26,115,000 after buying an additional 128,074 shares in the last quarter. Sio Capital Management LLC acquired a new position in shares of La Jolla Pharmaceutical in the 2nd quarter worth approximately $12,121,000. VHCP Management III LLC grew its stake in shares of La Jolla Pharmaceutical by 24.7% in the 2nd quarter. VHCP Management III LLC now owns 1,251,898 shares of the biopharmaceutical company’s stock worth $11,580,000 after purchasing an additional 248,298 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of La Jolla Pharmaceutical by 1.2% in the 2nd quarter. Vanguard Group Inc. now owns 1,045,292 shares of the biopharmaceutical company’s stock worth $9,669,000 after purchasing an additional 12,097 shares during the last quarter. Finally, Boxer Capital LLC acquired a new position in shares of La Jolla Pharmaceutical in the 2nd quarter worth approximately $5,319,000.

Several brokerages have recently issued reports on LJPC. Chardan Capital reaffirmed a “buy” rating on shares of La Jolla Pharmaceutical in a research note on Thursday, August 15th. BidaskClub cut shares of La Jolla Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Friday, September 27th. ValuEngine raised shares of La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Zacks Investment Research cut shares of La Jolla Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Thursday, August 8th. Finally, HC Wainwright set a $27.00 price objective on shares of La Jolla Pharmaceutical and gave the stock a “buy” rating in a research note on Thursday, August 29th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $15.50.

Shares of La Jolla Pharmaceutical stock traded down $0.05 during trading on Tuesday, hitting $6.70. The stock had a trading volume of 9,400 shares, compared to its average volume of 272,143. The stock has a 50 day simple moving average of $8.25 and a 200 day simple moving average of $8.58. The company has a market capitalization of $186.46 million, a PE ratio of -0.86 and a beta of 2.07. La Jolla Pharmaceutical has a 1 year low of $5.01 and a 1 year high of $16.44.

La Jolla Pharmaceutical Profile

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock.

Featured Story: The Role of a Fiduciary and Individual Investors

Institutional Ownership by Quarter for La Jolla Pharmaceutical (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.